Abbott Laboratories (ABT) Touches $86.53 High on Jul, 17; Cannell Capital Has Boosted Its Viad (VVI) Position

Abbott Laboratories (NYSE:ABT) Logo

The stock of Abbott Laboratories (NYSE:ABT) reached all time high today, Jul, 17 and still has $92.59 target or 7.00% above today’s $86.53 share price. This indicates more upside for the $152.65B company. This technical setup was reported by If the $92.59 PT is reached, the company will be worth $10.69 billion more. The stock increased 4.05% or $3.36 during the last trading session, reaching $86.53. About 2.28M shares traded. Abbott Laboratories (NYSE:ABT) has risen 23.36% since July 17, 2018 and is uptrending. It has outperformed by 18.93% the S&P500. Some Historical ABT News: 28/03/2018 - Abbott is taking its partnership with a diabetes care start-up one step further; 06/03/2018 - FDA Approves the World’s Smallest Mechanical Heart Valve for Pediatric Patients with Heart Defects; 20/04/2018 - Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023; 18/04/2018 - Dreyfus Third Century Adds Abbott, Exits Trimble; 10/04/2018 - Abbott says NAFTA “had to be updated” due to technology and intellectual property challenges; 29/03/2018 - Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor; 03/05/2018 - ABBOTT CITES FDA CLEARANCE OF ADVANCED MAPPING CATHETER; 05/04/2018 - ABBOTT SAYS ISS REPORT INCORRECT, UNRELIABLE; 07/03/2018 - Abbott’s Confirm Rx connects an insertable cardiac monitor to a smartphone app; 18/05/2018 - ABBOTT: WILL WORK W/ TEXAS LEGISLATURE TO FIND SOLUTIONS

Cannell Capital Llc increased Viad Corp (VVI) stake by 15% reported in 2019Q1 SEC filing. Cannell Capital Llc acquired 10,433 shares as Viad Corp (VVI)’s stock rose 12.74%. The Cannell Capital Llc holds 80,009 shares with $4.50 million value, up from 69,576 last quarter. Viad Corp now has $1.42B valuation. The stock increased 0.03% or $0.02 during the last trading session, reaching $69.97. About 1,975 shares traded. Viad Corp (NYSE:VVI) has risen 24.47% since July 17, 2018 and is uptrending. It has outperformed by 20.04% the S&P500. Some Historical VVI News: 02/05/2018 - Wells Capital Management Inc. Exits Position in Viad; 26/04/2018 - VIAD CORP - EXPECT 2018 CONSOLIDATED REVENUE TO INCREASE AT A LOW SINGLE-DIGIT RATE FROM 2017 FULL YEAR REVENUE; 22/05/2018 - VIAD CORP-EFFECTIVE MAY 18, CO’S UNIT EXECUTED SECOND AMENDMENT TO CREDIT AGREEMENT AND REAFFIRMATION OF GUARANTIES TO ITS REVOLVING CREDIT FACILITY; 04/05/2018 - Victory Capital Buys New 4.1% Position in Viad; 26/04/2018 - VIAD 1Q ADJ LOSS/SHR 49C, EST. LOSS/SHR 52C; 26/04/2018 - VIAD CORP VVI.N FY2018 SHR VIEW $2.73, REV VIEW $1.33 BLN — THOMSON REUTERS l/B/E/S; 21/04/2018 - DJ Viad Corp, Inst Holders, 1Q 2018 (VVI); 26/04/2018 - VIAD CORP QTRLY LOSS BEFORE OTHER ITEMS PER SHARE $0.49; 22/05/2018 - VIAD CORP - BMO HARRIS BANK N.A. IS A LENDER UNDER EXISTING $300 MLN CREDIT FACILITY - SEC FILING; 27/04/2018 - Viad Closes Below 50-Day Moving Average: Technicals

Since January 30, 2019, it had 1 buy, and 1 insider sale for $12.17 million activity. Contreras Jaime had sold 177,457 shares worth $12.42 million. 3,455 shares valued at $249,875 were bought by Stratton John G on Thursday, January 31.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $152.65 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 58.7 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: which released: “Abbott Laboratories Q2 2019 Earnings Preview - Seeking Alpha” on July 16, 2019, also with their article: “Abbott Laboratories Reports Q2 Earnings Beat - Benzinga” published on July 17, 2019, published: “Is Abbott Laboratories (NYSE:ABT) Investing Your Capital Efficiently? - Yahoo Finance” on July 02, 2019. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: and their article: “Earnings Season Starts With Beat From Citigroup; Other Banks, Netflix Report Later In Week - Benzinga” published on July 15, 2019 as well as‘s news article titled: “10 Stocks To Watch For July 17, 2019 - Benzinga” with publication date: July 17, 2019.

Among 3 analysts covering Abbott Labs (NYSE:ABT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abbott Labs has $9300 highest and $84 lowest target. $88.50’s average target is 2.28% above currents $86.53 stock price. Abbott Labs had 11 analyst reports since March 1, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, March 14 by Cowen & Co. The rating was maintained by Barclays Capital with “Buy” on Friday, March 8. Morgan Stanley maintained Abbott Laboratories (NYSE:ABT) on Tuesday, July 16 with “Overweight” rating. The stock of Abbott Laboratories (NYSE:ABT) has “Outperform” rating given on Thursday, June 13 by Wells Fargo.

Investors sentiment decreased to 0.82 in 2019 Q1. Its down 0.09, from 0.91 in 2018Q4. It turned negative, as 52 investors sold Abbott Laboratories shares while 617 reduced holdings. 143 funds opened positions while 408 raised stakes. 1.26 billion shares or 2.74% less from 1.29 billion shares in 2018Q4 were reported. Trustco Bank & Trust Corporation N Y reported 3.07% in Abbott Laboratories (NYSE:ABT). Thompson Siegel And Walmsley Ltd Co invested 0.01% of its portfolio in Abbott Laboratories (NYSE:ABT). Comml Bank reported 1,839 shares stake. Btr Management holds 107,430 shares or 1.65% of its portfolio. Assets Mgmt Limited Company owns 40,500 shares. Sg Americas Secs Ltd Liability Company holds 0.08% or 107,284 shares in its portfolio. Nelson Roberts Invest Advsrs Ltd Liability Company has invested 0.15% in Abbott Laboratories (NYSE:ABT). Daiwa Sb Invests Limited holds 0.03% in Abbott Laboratories (NYSE:ABT) or 1,760 shares. Rnc Capital Management Ltd Liability Corp stated it has 0.07% in Abbott Laboratories (NYSE:ABT). Perritt Capital Mgmt stated it has 0.27% in Abbott Laboratories (NYSE:ABT). Etrade Cap Ltd Com reported 65,149 shares. Pinnacle Wealth Management Advisory Group Incorporated Ltd Liability Corp has invested 0.13% in Abbott Laboratories (NYSE:ABT). Monetary Management Grp Inc Inc owns 24,745 shares for 0.78% of their portfolio. Mogy Joel R Invest Counsel owns 62,991 shares for 0.68% of their portfolio. Benin Mgmt reported 29,055 shares stake.

Cannell Capital Llc decreased Ring Energy Inc (NYSEMKT:REI) stake by 1.91 million shares to 1.13 million valued at $6.66M in 2019Q1. It also reduced Innovative Indl Pptys Inc stake by 11,633 shares and now owns 101,803 shares. Veracyte Inc (NASDAQ:VCYT) was reduced too.

Viad Corp (NYSE:VVI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.